[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352970-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352970-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","downregulation-of-thrb-drives-immune-microenvironment-suppression-and-poor-outcomes-acting-as-a-dual-biomarker-for-clear-cell-renal-cell-carcinoma","Downregulation of THRB drives immune microenvironment suppression and poor outcomes, acting as a dual biomarker for clear cell renal cell carcinoma","","Clear cell renal cell carcinoma (ccRCC) often resists targeted and immune therapies, creating an urgent need for predictive biomarkers. Thyroid hormone receptor beta (THRB) is a nuclear transcription factor, yet its immunomodulatory role in ccRCC is unclear. TCGA-KIRC and independent validation cohorts link THRB downregulation with advanced disease, worse survival, immunosuppressive microenvironment features, and reduced sensitivity to sunitinib/pazopanib, supporting THRB as a dual biomarker.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/downregulation-of-thrb-drives-immune-microenvironment-suppression-and-poor-outcomes-acting-as-a-dual-biomarker-for-clear-cell-renal-cell-carcinoma/352970/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/downregulation-of-thrb-drives-immune-microenvironment-suppression-and-poor-outcomes-acting-as-a-dual-biomarker-for-clear-cell-renal-cell-carcinoma/352970.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are predictive biomarkers needed for clear cell renal cell carcinoma?","Question",{"text":63,"@type":64},"ccRCC frequently shows resistance to targeted and immune therapies, and treatment responses vary due to tumor heterogeneity. This makes reliable predictors necessary to identify patients likely to benefit from therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and analyses were used to study THRB in ccRCC?",{"text":68,"@type":64},"The study used TCGA-KIRC data and validation cohorts (GSE46699/53757). Analyses included differential expression, survival analysis, immune infiltration estimation, functional enrichment (GO/KEGG/GSEA), and drug sensitivity prediction.",{"name":70,"@type":61,"acceptedAnswer":71},"How does THRB downregulation relate to immune microenvironment and outcomes?",{"text":72,"@type":64},"THRB downregulation correlates with advanced stage/grade and poorer overall and disease-specific survival. It associates with immune regulation pathways, an immunosuppressive immune landscape, and higher expression of T-cell exhaustion markers, indicating worse prognosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352970,1790181884,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Peng et al. BMC Cancer (2026) 26:666 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15832-7](https://doi.org/10.1186/s12885-026-15832-7)  \nRESEARCH Open Access  \nDownregulation of THRB drives immune microenvironment suppression and poor outcomes, acting as a dual biomarker for clear cell renal cell carcinoma  \nSuzhen Peng1,2†, Xiao Liu1,2†, Weizi Sun1, Jiegang Hu1, Zhiwei Tang1, Shitong Wang1 and Zhongshi He 1,2*  \nAbstract  \nBackground Clear cell renal cell carcinoma (ccRCC) frequently resists targeted and immune therapies, necessitating predictive biomarkers. Thyroid hormone receptor beta (THRB), a nuclear transcription factor at 3p21-25, shows tumorsuppressive roles in other cancers but its immunomodulatory function in ccRCC remains unclear.  \nMethods Using TCGA-KIRC data (535 tumors, 72 normals) and validation cohorts (GSE46699/53757), we analyzed THRB expression, clinical correlations, and immune associations via differential expression (limma), survival analysis (Kaplan-Meier/Cox regression), immune infiltration (CIBERSORT/ESTIMATE), functional enrichment (GO/KEGG/GSEA), and drug sensitivity (pRRophetic) .  \nResults THRB was significantly downregulated in ccRCCand 11 other cancers (P \u003C 0. 05), correlating with advanced stage/grade (P \u003C 0. 001) and poorer survival (OS HR = 2 . 33, DSS HR = 3 .43; P \u003C 0. 001) . Multivariate analysis confirmed its independent prognostic value (HR = 0 . 69, P = 0 . 007) . Functionally, THRB associated with immune regulation (T-cell activation, PD-1/PD-L1 pathways) and distinct immune infiltration patterns. High-THRB tumors were enriched for resting immune cells and M2 macrophages, while low-THRB tumors showed higher fractions of CD8⁺ T cells and regulatory T cells (Tregs), along with elevated expression ofT-cell exhaustion markers (all P \u003C 0. 01) . This suggests a complex role for THRB in shaping the immune landscape. THRB negatively correlated with TMB (r=-0 . 26, P \u003C 0. 001) and inhibitory checkpoints (LGALS9, CD70), but positively with VTCN1 . In silico analysis predicted that low-THRB patients might exhibit reduced sensitivity to sunitinib/pazopanib (higher IC50, P \u003C 0. 001) .  \nConclusion THRB downregulation is associated with poor prognosis, an immunosuppressive microenvironment, and resistance to targeted therapies in ccRCC. These findings suggest its potential as a dual biomarker, implying that THRB loss may contribute to immune dysregulation and therapy resistance. Restoring THRB-mediated pathways may offer novel therapeutic strategies, though its predictive value for immunotherapy requires future clinic validation.  \n†Suzhen Peng and Xiao Liu contributed equally to this work.  \n*Correspondence: Zhongshi He[hezhongshi83@163.com](hezhongshi83@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nPeng et al. BMC Cancer (2026) 26:","cbCaivUIjMt74qEf","https://ap.wps.com/l/cbCaivUIjMt74qEf","pdf",3860725,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"Why are predictive biomarkers needed for clear cell renal cell carcinoma?\",\"answer\":\"ccRCC frequently shows resistance to targeted and immune therapies, and treatment responses vary due to tumor heterogeneity. This makes reliable predictors necessary to identify patients likely to benefit from therapy.\"},{\"question\":\"What data and analyses were used to study THRB in ccRCC?\",\"answer\":\"The study used TCGA-KIRC data and validation cohorts (GSE46699/53757). Analyses included differential expression, survival analysis, immune infiltration estimation, functional enrichment (GO/KEGG/GSEA), and drug sensitivity prediction.\"},{\"question\":\"How does THRB downregulation relate to immune microenvironment and outcomes?\",\"answer\":\"THRB downregulation correlates with advanced stage/grade and poorer overall and disease-specific survival. It associates with immune regulation pathways, an immunosuppressive immune landscape, and higher expression of T-cell exhaustion markers, indicating worse prognosis.\"}]","Downregulation of THRB drives immune microenvironment suppression and poor outcomes, acting as a dual biomarker for clear cell renal cell carcinoma | PDF",1790102344,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/821333517224611cfabfbc3d27b54ba0.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d27c0765899d60c2a57c5f97eb4f1cc.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6244e1815c52892a99b8b2b1a97f09d.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/422c4850b223ac2fd2ec8218464fc761.webp",980,1306]